Pharm Aid Ltd pharmaceutical company was founded in 2017 with the aim of transferring technologies for the production of innovative biotechnological product to Russia.
Today, Pharm Aid is the largest Russian supplier of vaccines for the prevention of rotavirus infection and is implementing a project to build a production facility for innovative combined immunobiological products intended for the prevention and treatment of various diseases at the Vorsino Industrial Park in the Kaluga Region.
Our Vision
To protect the populations of Russia and the CIS countries with accessible and high-quality medical technologies, making the best global biopharmaceutical products available to everyone. In doing so, we participate in the development and modernization of the biopharmaceutical industry in Russia, in line with the Russian Federation's state strategy to achieve independence from the import of essential medicines.
Our Values
We understand that health cannot be postponed, which is why we strive to bring modern, innovative immunobiological products to the market and make them accessible, so more people can benefit from high-quality prevention and therapy.
Collaboration for a Better Future
We are developing international cooperation and, in partnership with leading global pharmaceutical companies, localize advanced biotechnological developments in Russia. This ensures sustainable development and effective modernization of the domestic pharmaceutical industry and will provide the country with new, accessible medicines.
Production
Establishing our own pharmaceutical production is our contribution to the implementation of the Russian Federation's state strategy for import substitution of essential medicines.
The modern production complex at the Vorsino Industrial Park in the Kaluga Region is aimed at producing a wide range of innovative multi-component products using advanced biotechnology.
The plant is designed to meet biosafety requirements for working with pathogenic biological agents of Groups III-IV (WHO: BSL-1, BSL-2), as well as the GMP requirements of Russia and the Eurasian Economic Union.
The complex includes two workshops—for the production of live and inactivated vaccines. Both workshops are equipped with high-speed lines capable of meeting the needs of Russia and the CIS countries, and have sufficient flexibility to produce multiple vaccines, facilitating production ramp-up in case of emergencies or disease outbreaks. The site will also feature a quality control laboratory, equipped with high-tech equipment with centralized computer management.
